Lilly's anti-diabetic Bydureon launched first in the UK
This article was originally published in Scrip
Executive Summary
Lilly has launched its once-weekly glucagon-like peptide (GLP-1) receptor agonist, Bydureon (exenatide 2mg powder and solvent for prolonged release suspension for injection), for the treatment of type 2 diabetes in the UK, the product's first market.